Histone Deacetylase Inhibitors: Overview and Perspectives

By Milos Dokmanovic, Cathy Clarke, PA Marks. Molecular Cancer Research, 2007

1,159 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0cf582141866aa45766eae1f3e5c7a3aba125199

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. W-S Xu
2. R. Jenkins
3. PA Marks

In Oncology

1. PA Marks

Citations in the corpus

• HDAC family: What are the cancer relevant targets? (2009, background): “An increasing number of non-histone proteins are recognized as substrates of HDACs such as p53, E2Fs, GATA1, Bcl-6, Stat3, HMGs, HSP90, NF-jB, tubulin, importin, nuclear hormone receptors, and b-catenin (for review see [21]).”
• The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. (2013, positive): “3K27M tumor patients (Dokmanovic et al. 2007; McCabe et al. 2012).”
• Combination therapy in combating cancer (2017, background): “For example, HDAC10 (one class of HDAC) have shown to be increased in gastric cancers [95].”
• Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009, background): “1) [Bolden et al., 2006; Minucci and Pelicci, 2006; Glozak and Seto, 2007; Jones and Baylin, 2007; Rasheed et al., 2007; Xu et al., 2007; Dokmanovic et al., 2007a; Blackwell et al., 2008; Moradei et al., 2008; Shankar and Srivastava, 2008].”